Myelodysplastic Syndrome Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical

Myelodysplastic Syndrome Pipeline constitutes 120+ key companies continuously working towards developing 125+ Myelodysplastic Syndrome treatment therapies, analyzes DelveInsight.

Myelodysplastic Syndrome Overview:

Myelodysplastic syndrome (MDS) is a diverse group of blood disorders characterized by abnormal development of hematopoietic stem cells, resulting in ineffective blood cell production in the bone marrow. In some cases, MDS can progress to acute myeloid leukemia (AML). The condition is most commonly diagnosed in individuals over 65 years old and is marked by reduced levels of red blood cells (RBCs), white blood cells (WBCs), and platelets. The disease course varies among patients.

MDS can arise due to multiple factors, including environmental exposures to chemicals like benzene, radiation, and previous chemotherapy treatments, though in many elderly patients, the cause remains unknown. Additionally, bone marrow failure syndromes such as acquired aplastic anemia and Fanconi anemia may increase the risk of developing MDS and sometimes present with similar features.

Request for a detailed insights report on Myelodysplastic Syndrome pipeline insights @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Myelodysplastic Syndrome Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

DelveInsight's Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Myelodysplastic Syndrome treatment.
In January 2025, Keros Therapeutics Inc. initiated a clinical trial (KER-050-D301) to assess the efficacy and safety of elritercept (KER-050) compared to a placebo in adults with transfusion-dependent anemia associated with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS), now classified as myelodysplastic neoplasms. The study includes multiple phases: a Screening Period, a Double-Blind Treatment Period, a Safety Follow-Up Period, and a Long-Term Follow-Up Period.
Meanwhile, Bristol-Myers Squibb launched a study to evaluate the effectiveness and safety of Luspatercept versus epoxetin alfa in treating anemia in adults with very low, low, or intermediate-risk MDS (as per IPSS-R criteria). This trial focuses on ESA-naïve patients who are non-transfusion dependent (NTD).
Key Myelodysplastic Syndrome companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others are evaluating new drugs for Myelodysplastic Syndrome to improve the treatment landscape.
Promising Myelodysplastic Syndrome pipeline therapies in various stages of development include Tamibarotene, CA-4948, RVU120, MNV-201, and others.

Myelodysplastic Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Myelodysplastic Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Myelodysplastic Syndrome market.

Download our free sample page report on Myelodysplastic Syndrome pipeline insights @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myelodysplastic Syndrome Emerging Drugs

Tamibarotene: Syros Pharmaceuticals
CA-4948: Curis
RVU120: Ryvu Therapeutics
MNV-201: Minovia Therapeutics

Myelodysplastic Syndrome Companies

Around 120 prominent companies are actively working on developing therapies for Myelodysplastic Syndrome. Among them, Syros Pharmaceuticals has a drug candidate in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 125+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Companies: Myelodysplastic Syndrome Clinical Trials and advancements @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myelodysplastic Syndrome Pipeline Therapeutic Assessment
• Myelodysplastic Syndrome Assessment by Product Type
• Myelodysplastic Syndrome By Stage
• Myelodysplastic Syndrome Assessment by Route of Administration
• Myelodysplastic Syndrome Assessment by Molecule Type

Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Myelodysplastic Syndrome Key Companies
15. Myelodysplastic Syndrome Key Products
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.